All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
REZPEG in the treatment of plaque psoriasis: Results from a phase Ib trial
By Ella Dixon
|
In inflammatory diseases such as psoriasis, Tregs are impaired and there is limited evidence on the therapeutic potential of Treg restoration.1 REZPEG selectively expands CD25bright regulatory T cells without increasing conventional T cells, suggesting it restores immune tolerance and balances immune responses, which are dysregulated in psoriasis.1 A phase Ib randomized, placebo-controlled study (NCT04119557) published in Nature Communicationsinvestigated REZPEG in 30 patients with chronic plaque psoriasis for 12 weeks, with follow-up to 19 weeks. Responders at Week 19 had follow-up through Week 48.
|
| Key learnings |
| Patients treated with REZPEG showed a LS mean improvement from baseline in PASI scores compared with placebo at Week 12 and Week 19 (44.5% vs 26.2% and 51.4% vs 19.9%, respectively), demonstrating sustained efficacy. |
| REZPEG was well tolerated, with TEAEs reported by 70.8% of patients. All except one TEAE were of mild-to-moderate severity, and no serious adverse events were reported. Injection site reactions were the most common treatment-related side effects. |
| REZPEG treatment led to long-term, treatment-free disease control, with a sustained decrease in psoriasis symptoms, highlighting the potential of REZPEG in providing prolonged remission and reducing treatment burden. |
| REZPEG has the potential to be an alternative to existing therapies for psoriasis, particularly for patients with inadequate responses to current biologics or immunosuppressants. |
Abbreviations: LS, least-squares; PASI, Psoriasis Area and Severity Index; REZPEG, rezpegaldesleukin; TEAE, treatment-emergent adverse event; Tregs, regulatory T cells.
- Silverberg JI, Rosmarin D, Chovatiya R, et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024;15(1):9230. DOI: 1038/s41467-024-53384-1
More about...
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox